Conceptos Categóricos

Crónicas de autores

David Conde-Estévez *

Autor invitado por SIIC

Revisión crítica y aséptica de la evidencia en el tratamiento de extravasaciones por antraciclinas y de la situación actual

TRATAMIENTO DE LAS EXTRAVASACIONES POR ANTRACILINAS CON DEXRAZOXANO

En la actualidad, el único fármaco autorizado para tratar las extravasaciones por antraciclinas es el dexrazoxano. A pesar de ello, otras aproximaciones terapéuticas están disponibles y han demostrado su eficacia como es el caso del dimetilsulfóxido (DMSO) al 90-99%. Se plantea una revisión crítica y aséptica de la evidencia publicada de ambos y la situación actual. La conclusión a la que llegamos es que con la evidencia actual no podemos recomendar inequívocamente una alternativa o otra. Debería realizarse un estudio comparativo entre ambas aproximaciones terapéuticas a fin de poder determinar el mejor manejo en el caso de extravasaciones por antraciclinas.

*David Conde-Estévez
describe para SIIC los aspectos relevantes de su trabajo
TREATMENT OF ANTHRACYCLINE EXTRAVASATIONS USING DEXRAZOXANE
Clinical & Translational Oncology,
16(1):11-17 Ene, 2014

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Department Of Pharmacy, Hospital Universitari del Mar. Parc de Salut Mar, Universitat Autònoma de Barcelona, Barcelona, España
Imprimir nota
Referencias bibliográficas
Mullin S, Beckwith MC, Tyler LS. Prevention and Management of Antineoplastic Extravasation Injury. Hosp Pharm. 2000;35:57–74.
Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004;15(6):858–62. CrossRef
Alfaro-Rubio A, Sanmartin O, Requena C, Llombart B, Botella-Estrada R, Nagore E, et al. Extravasation of cytostatic agents: a serious complication of oncological treatment. Actas Dermosifiliogr. 2006;97(3):169–76. CrossRef
Watanabe H, Ikesue H, Yoshida M, Yamamoto N, Sakamoto S, Koga T, et al. Protection against the extravasation of anticancer drugs by standardization of the management system. Hosp Pharm. 2008;43(7):571–6. CrossRef
Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol. 2006;33(1):139–43. CrossRef
Reeves D. Management of anthracycline extravasation injuries. Ann Pharmacother. 2007;41(7):1238–42. CrossRef
Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF, Kaplan RS. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol. 1988;6(11):1732–5.
Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol. 1995;13(11):2851–5.
Creus N, Mateu J, Masso J, Codina C, Ribas J. Toxicity to topical dimethyl sulfoxide (DMSO) when used as an extravasation antidote. Pharm World Sci. 2002;24(5):175–6. CrossRef
Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol. 2003;14(Suppl 3):iii26–30.
Vano-Galvan S, Jaen P. Images in clinical medicine. Extravasation of epirubicin. N Engl J Med. 2009;360(20):2117. CrossRef
Kane RC, McGuinn WD Jr, Dagher R, Justice R, Pazdur R. Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. Oncologist. 2008;13(4):445–50. CrossRef
Hasinoff BB. The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Investig Drugs. 2008;17(2):217–23. CrossRef
Thougaard AV, Langer SW, Hainau B, Grauslund M, Juhl BR, Jensen PB, et al. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage. Toxicology. 2010;269(1):67–72. doi:10.1016/j.tox.2010.01.007. CrossRef
Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res. 2000;6(9):3680–6.
Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol. 2001;12(3):405–10. CrossRef
Langer SW, Thougaard AV, Sehested M, Jensen PB. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol. 2006;57(1):125–8. CrossRef
Langer SW, Sehested M, Jensen PB, Buter J, Giaccone G. Dexrazoxane in anthracycline extravasation. J Clin Oncol. 2000;18(16):3064.
Bos AM, van der Graaf WT, Willemse PH. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. Acta Oncol. 2001;40(4):541–2. CrossRef
Jensen JN, Lock-Andersen J, Langer SW, Mejer J. Dexrazoxane—a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Surg Hand Surg. 2003;37(3):174–5. CrossRef
El-Saghir N, Otrock Z, Mufarrij A, Abou-Mourad Y, Salem Z, Shamseddine A, et al. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol. 2004;5(5):320–1. CrossRef
Frost A, Gmehling D, Azemar M, Unger C, Mross K. Treatment of anthracycline extravasation with dexrazoxane—clinical experience. Onkologie. 2006;29(7):314–8. CrossRef
Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007;18(3):546–50. CrossRef
EMA. Product information: Savene-H-C-682-N-004 (2008) http://www.emea.europa.eu/humandocs/PDFs/EPAR/savene/068206es1.pdf. Accessed 7 Jul 2013.
Tyson AM, Gay WE. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation. Ann Pharmacother. 2010;44(5):922–5. CrossRef
Conde-Estevez D, Saumell S, Salar A, Mateu-de Antonio J. Successful dexrazoxane treatment of a potentially severe extravasation of concentrated doxorubicin. Anticancer Drugs. 2010;21(8):790–4. doi:10.1097/CAD.0b013e32833d903200001813-201009000-00009. CrossRef
Arroyo PA, Perez RU, Feijoo MA, Hernandez MA. Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation. J Cancer Res Ther. 2010;6(4):573–4. doi:JCanResTher_2010_6_4_573_7708110.4103/0973-1482.77081. CrossRef
Vos FY, Lesterhuis WJ, Bruggemann RJ, Graaf WT. Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment. Anticancer Drugs. 2012;23(1):139–40. doi:10.1097/CAD.0b013e32834be51a. CrossRef
Fontaine C, Noens L, Pierre P, De Greve J. Savene(R) (dexrazoxane) use in clinical practice. Support Care Cancer. 2012;20(5):1109–12. doi:10.1007/s00520-012-1382-2. CrossRef
Muthuramalingam S, Gale J, Bradbury J. Dexrazoxane efficacy for anthracycline extravasation: use in UK clinical practice. Int J Clin Pract. 2013;67(3):244–9. doi:10.1111/ijcp.12103. CrossRef
Langer SW, Thougaard AV, Sehested M, Jensen PB. Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane. Cancer Chemother Pharmacol. 2012;69(2):573–6. doi:10.1007/s00280-011-1794-6. CrossRef
Stanley A. Position Statement on dexrazoxane in the treatment of anthracycline extravasation. The National Extravasation Information Service. UK. 2007. http://www.extravasation.org.uk/Dexrazoxane.htm. Accessed 7 Jul 2013.
Evans L. North Trent Cancer Network—Extravasation Guidelines V4. 2011. http://www.northtrentcancernetwork.nhs.uk/Chemotherapy-Guidelines/Microsoft%20Word%20-%20B-Extravasation%20Guidelines%20v4.pdf. Accessed 6 Jul 2013.
Consortium SM. Re-submission dexrazoxane 500 mg vial of powder for intravenous infusion (Savene®) No. (361/07) TopoTarget A/S. 2008. http://www.scottishmedicines.org.uk/files/dexrazoxane__Savene__Resubmission_FINAL_September_2008.doc_for_website.pdf. Accessed 6 Jul 2013.
BCCA. Prevention and management of extravasation of chemotherapy III-20. 2012. http://www.bccancer.bc.ca/NR/rdonlyres/B10C0DC3-D799-45E8-8A61-A93F00906737/59243/III_20_ExtravasationManagement_1Jun2013.pdf. Accessed 6 Jul 2013.
Anonymous. Dexrazoxane: new indication. Anthracycline extravasation: continue using dimethyl sulfoxide. Prescrire Int 2009;18(99):6–8.
Wengstrom Y, Margulies A, European Oncology Nursing Society Task F. European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs. 2008;12(4):357–61. CrossRef
Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F et al. Management of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines. Ann Oncol. 2012;23(suppl 7):vii167–vii73. doi:10.1093/annonc/mds294.
Conde-Estevez D, Mateu-de Antonio J. Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol. 2013;24(4):1128–9; author reply 9–30. doi:10.1093/annonc/mdt021 mdt021.
Otros artículos de David Conde-Estévez

Conde-Estevez D, Mateu-de Antonio J. Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol. 2013;24(4):1128–9; author reply 9–30. doi:10.1093/annonc/mdt021 mdt021. Conde-Estevez D, Saumell S, Salar A, Mateu-de Antonio J. Successful dexrazoxane treatment of a potentially severe extravasation of concentrated doxorubicin. Anticancer Drugs. 2010;21(8):790–4. doi:10.1097/CAD.0b013e32833d903200001813-201009000-00009. Conde-Estévez D, Salas E, Albanell J. Survey of oral chemotherapy safety and adherence practices of hospitals in Spain. Int J Clin Pharm. 2013 Dec;35(6):1236-44. doi: 10.1007/s11096-013-9858-9. Epub 2013 Oct 16. Conde-Estévez D, Mateu-de Antonio J. [Update in the management of extravasations of cytocytostatic agent]. Farm Hosp. 2012 Jan-Feb;36(1):34-42. doi:10.1016/j.farma.2011.01.002. Epub 2011 Jul 27. Review. Spanish.

Para comunicarse con David Conde-Estévez mencionar a SIIC como referencia:
dconde@hospitaldelmar.cat

Autor invitado
5 de marzo, 2014
Descripción aprobada
27 de marzo, 2014
Reedición siicsalud
7 de junio, 2021

Acerca del trabajo completo
TRATAMIENTO DE LAS EXTRAVASACIONES POR ANTRACILINAS CON DEXRAZOXANO

Título original en castellano
TRATAMIENTO CON DESRAZOXANO DE LAS EXTRAVASACIONES POR ANTRACILINAS

Autor


Acceso a la fuente original
Clinical & Translational Oncology
http://www.springer.com/medicine/oncology/journal/12094

El artículo se relaciona estrictamente con las especialidades de siicsalud


ua40317
-->